Investor Profile: RA Capital Management — Thesis, Cheque Size & How to Apply

RA Capital Management is a Boston-based, multi-stage investment manager dedicated to evidence-based investing in healthcare and life science companies. Founded in 2004, according to the firm's own releases, it funds companies developing drugs, medical devices, diagnostics, services and research tools, from private seed rounds to public follow-on financings, allowing management teams to drive value creation from inception through commercialisation and beyond.

Thesis

The firm's thesis is evidence before enthusiasm. Its knowledge engine is TechAtlas, an internal research division that maps competitive landscapes in therapeutic areas, puts data into context and originates conviction in new ideas. Alongside investing, the firm builds companies through Raven, its company creation team, which offers entrepreneurs a collaborative platform to explore novel and re-imagined science. The through-line is scientific diligence: back the medicine or tool the evidence supports, then stay with it across stages.

Sectors and stages

RA Capital invests across most therapeutic areas and all stages, from discovery through commercialisation. Its core sectors are healthcare, life sciences and planetary health, spanning drugs, medical devices, diagnostics, healthcare services and research tools. It provides seed funding to startups and leads private, IPO and follow-on financings for portfolio companies, a crossover model designed to let teams create value with fewer capital concerns as they mature.

Fund size and cheque size

The firm reported more than 150 employees and over $10 billion in assets under management in its 2024 structured capital announcement. Its $120 million Planetary Health Fund, announced in 2025, extended the platform into planetary health alongside healthcare. Its second venture fund raised $461 million in 2020. On cheque size, the firm's own FAQ says it might invest under $1 million in a very small company's seed round, and has invested as much as $75 million in a single round, with the deciding factor being whether the return is likely to be impactful for the fund.

Portfolio

Portfolio names confirmed across the sources read include Moderna, Beam Therapeutics and Relay Therapeutics, alongside POINT Biopharma and Shockwave Medical. The pattern is consistent: platform therapeutics and drug developers where deep scientific diligence can separate real breakthroughs from fashionable science. The firm also invests in public healthcare and life science companies, so its portfolio spans private company formation and public-market positions in the same sectors.

Partners and programmes

Peter Kolchinsky is founder and managing partner, and Rajeev Shah is managing partner. Jeremy Lack and Adam Kaye joined as senior managing directors and partners for Structured Capital Solutions, launched in 2024 to offer flexible equity, debt, royalty and hybrid financing to commercial-stage companies. The named programmes that matter most to founders are therefore TechAtlas for research, Raven for company creation, and Structured Capital Solutions for later, more complex financings.

How to apply for funding from RA Capital Management

RA Capital's own FAQ gives the route directly: if you do not know anyone at the firm, email the appropriate person listed on its Contact page. Include a description of your project, ideally with indication, target and concept, plus comparable companies and competitors, so the team can route you to the right people. There is one contact for already-formed companies and another for people working on forming a company, but the firm says a pitch sent to either contact will reach the right person.